We came across a bullish thesis on Zenas BioPharma, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on ZBIO. Zenas BioPharma, Inc.'s share was trading at $27.02 as of February 19th. ZBIO’s trailing P/E was 1.93 according to Yahoo Finance.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. ZBIO is transitioning from a pre-revenue stage to commercialization, with analysts projecting revenues to rise from near...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.